Actively Recruiting
Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.
Led by Aalborg University Hospital · Updated on 2024-06-28
120
Participants Needed
1
Research Sites
282 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.
CONDITIONS
Official Title
Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients > 18 years
- Diagnosed with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
- Starting treatment with infliximab or adalimumab
- Co-treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARD) or glucocorticoids is allowed
- No new biological disease-modifying antirheumatic drug (bDMARD) started at the time of sampling
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of rheumatology
Aalborg, Denmark, 8000
Actively Recruiting
Research Team
K
Karen B Lauridsen, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here